Pending FDA review and approval, research findings pave way for Akili ’s EVO to become first brain training platform prescribed for ADHD

Akili Achieves Primary Efficacy Endpoint in ADHD Trial (MD magazine): “Boston-based Akili Interactive has announced top-line results from the STARS-ADHD pivotal study of its investigational digital therapeutic medicine AKL-T01, in treatment of pediatric attention-deficit/hyperactivity disorder (ADHD)…The digital medicine, AKL-T01, is a video game for patients to play on tablet devices. It uses the same storytelling and reward mechanisms as standard videogames; however, it features mechanisms to act on neural systems and algorithms that dial the level of stimulus up or down, meeting the needs of the patient. In the STARS-ADHD randomized, controlled trial of 348 children and adolescents diagnosed with ADHD, AKL-T01 showed a statically significant improvement compared to an active control group on the predefined primary endpoint, a change in the Attention Performance Index (API), a composite score from the Test of Variables of Attention (TOVA)… After the 4-week period, an assessment measured changes from baseline on standard measures of attention, memory and impulsivity. Children and adolescents that received AKL-T01 showed a statistically meaningful improvement in attentional functioning on the API…Engineered as a therapeutic active treatment for cognitive deficiency, AKL-T01 is built on Akili’s patented Project: EVO technology platform that allows selective targeting and activation of specific cognitive neural systems in the brain that exhibit deficiency from various...
Source: SharpBrains - Category: Neuroscience Authors: Tags: Attention and ADD/ADHD Cognitive Neuroscience Health & Wellness Technology Akili Akili Interactive Brain-Training depression digital medicine digital therapeutic digital therapies FDA impulsivity memory neural systems STARS-A Source Type: blogs